Skip to main content

Table 2 Details of the statistical results of the fMRI analyses

From: Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study

Anatomical region

Cluster size

(voxels), n

T value

MNI coordinates

(x,y,z)

A) Main Effect: Pooled visits, all participants (n = 40),

threshold: p < 0.001 [uncorrected], T > 3.31, minimum, cluster extent 25 voxels, df = 39

L cerebellum exterior

4501

7.21

-32,-56,-32

R central operculum

3139

7.17

50,2,3

L cerebellum exterior

3156

6.79

-25,-65,-49

R cerebellum exterior

1628

6.15

36,-52,-29

L posterior insula

329

5.33

-36,-10,4

L anterior insula

121

5.13

-35,5,4

Cerebellar vermal lobules I-V

417

5.04

0,-49,-15

R cerebellum exterior

765

4.93

32,-56,-49

R posterior insula

115

4.42

40,-14,-5

L brainstem/ spinal trigeminal nucleus

127

4.41

-3,-42,-49

R brainstem/ spinal trigeminal nucleus

122

4.41

7,-39,-47

L cerebellum exterior

111

4.38

-13,-44,-22

R thalamus

65

4.18

6,-28,-2

Cerebellar vermal lobules XIII-X

146

4.15

0,-61,-35

R cerebellum exterior

158

4.12

16,-57,-47

R posterior insula

27

4.09

41,-1,-16

R cerebellum exterior

76

3.94

21,-64,-16

R putamen

86

3.92

24,0,-12

R anterior insula

30

3.92

38,7,-16

L central operculum

96

3.87

-50,6,3

R putamen

29

3.87

30,-21,1

Cerebellar vermal lobules I-V

72

3.79

-11,-59,-16

L posterior insula

35

3.79

-39,-15,-6

R pallidum

27

3.63

20,3,1

B) Response And Group Variance (n = 40)

contrast [ammonia–air puffs]visit1 > [ammonia–air puffs]visit2,

Verum Response>Placebo Response,

threshold p < 0.001 [uncorrected], T > 3.32, minimum cluster extent 20voxels, df = 37)

R central operculum

43

4.19

56,8,0

L putamen

110

3.91

-20,16,0

L parahippocampal gyrus

20

3.78

-4,-6,1

R putamen

24

3.74

25,10,-4

L putamen

37

3.69

-26,6,-6

  1. A) Main findings of trigeminal pain processing in all participants with both visits pooled. The imaging results are proofing trigeminal nociceptive stimulation and showing typical areas involved in pain processing. B) One-Sample t-Test (n=40) with regressor weighting for group (Verum>Placebo) including the Response (relative reduction in monthly headache days). Main findings specific for being a verum responder